High Density Lipoproteins-Based Therapies for Cardiovascular Disease

dc.contributor.author	Gao, Xuan	en_US
dc.contributor.author	Yuan, Shujun	en_US
dc.date.accessioned	2012-01-12T17:34:25Z
dc.date.available	2012-01-12T17:34:25Z
dc.date.copyright	2010
dc.date.issued	2010-07
dc.identifier.citation	Gao, Xuan, Shujun Yuan. "High density lipoproteins-based therapies for cardiovascular disease" Journal of Cardiovascular Disease Research 1(3): 99-103. (2010)
dc.identifier.issn	0976-2833
dc.identifier.uri	https://hdl.handle.net/2144/3396
dc.description.abstract	Atherosclerosis is the leading cause of death in developed countries. High density lipoproteins (HDL) cholesterol level correlates inversely with the risk of cardiovascular diseases. Thus, HDL has obtained lots of interest for drug development. In this review, we summarized the mechanisms for the antiatherogenic function of HDL, current HDL-based drugs in clinical use and the future direction for HDL-based therapy development.	en_US
dc.description.sponsorship	National Institutes of Health (GM067260, HL026355)	en_US
dc.language.iso	en
dc.publisher	Medknow Publications	en_US
dc.rights	Copyright Journal of Cardiovascular Disease Research	en_US
dc.rights.uri	http://creativecommons.org/licenses/by/2.0/
dc.subject	High density lipoprotein	en_US
dc.subject	Reverse cholesterol transport	en_US
dc.subject	Atherosclerosis	en_US
dc.subject	Drug development	en_US
dc.title	High Density Lipoproteins-Based Therapies for Cardiovascular Disease	en_US
dc.type	Article	en_US
dc.identifier.doi	10.4103/0975-3583.70898
dc.identifier.pmid	21187875
dc.identifier.pmcid	2982209

Except where otherwise noted, this item's license is described as Copyright Journal of Cardiovascular Disease Research